# A Biomarker-driven Therapeutic Strategy for Esophageal Cancer Chemoradiotherapy in Patients With Resectable Adenocarcinoma of the ESophagus and Esophagogastric Junction

> **NCT04269083** · NA · UNKNOWN · sponsor: **Azienda Ospedaliera Universitaria Integrata Verona** · enrollment: 128 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **OTHER:** BIRC3

## Key facts

- **NCT ID:** NCT04269083
- **Lead sponsor:** Azienda Ospedaliera Universitaria Integrata Verona
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-24
- **Primary completion:** 2024-03-24
- **Final completion:** 2024-08-24
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2020-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04269083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04269083, "A Biomarker-driven Therapeutic Strategy for Esophageal Cancer Chemoradiotherapy in Patients With Resectable Adenocarcinoma of the ESophagus and Esophagogastric Junction". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04269083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*